TY - JOUR
T1 - Recent progress in vaccines against fungal diseases
AU - Cassone, Antonio
AU - Casadevall, Arturo
N1 - Funding Information:
The Authors wish to thank Mrs Anna Marella for help in the preparation of the manuscript. The contribution of the National AIDS project to A. Cassone (grant no. F/1230 ) is also acknowledged. AC is supported by 5R01HL059842 , 5R01AI033774 , 5R37AI033142 , and 5R01AI052733 and Center for AIDS Research at Einstein .
PY - 2012/8
Y1 - 2012/8
N2 - Diseases caused by fungi are increasingly impacting the health of the human population and now account for a large fraction of infectious disease complications in individuals with impaired immunity or breached tissue defenses. Antifungal therapy is often of limited effectiveness in these patients, resulting into treatment failures, chronic infections and unacceptable rates of mortality, morbidity and their associated costs. Consequently there is a real medical need for new treatments and preventive measures to combat fungal diseases and, toward this goal, safe and efficacious vaccines would constitute major progress. After decades of complacency and neglect of this critically important field of research, remarkable progress has been made in recent years. A number of highly immunogenic and protective vaccine formulations in preclinical setting have been developed, and at least two have undergone Phase 1 clinical trials as preventive and/or therapeutic tools against candidiasis.
AB - Diseases caused by fungi are increasingly impacting the health of the human population and now account for a large fraction of infectious disease complications in individuals with impaired immunity or breached tissue defenses. Antifungal therapy is often of limited effectiveness in these patients, resulting into treatment failures, chronic infections and unacceptable rates of mortality, morbidity and their associated costs. Consequently there is a real medical need for new treatments and preventive measures to combat fungal diseases and, toward this goal, safe and efficacious vaccines would constitute major progress. After decades of complacency and neglect of this critically important field of research, remarkable progress has been made in recent years. A number of highly immunogenic and protective vaccine formulations in preclinical setting have been developed, and at least two have undergone Phase 1 clinical trials as preventive and/or therapeutic tools against candidiasis.
UR - http://www.scopus.com/inward/record.url?scp=84865278725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865278725&partnerID=8YFLogxK
U2 - 10.1016/j.mib.2012.04.004
DO - 10.1016/j.mib.2012.04.004
M3 - Review article
C2 - 22564747
AN - SCOPUS:84865278725
SN - 1369-5274
VL - 15
SP - 427
EP - 433
JO - Current Opinion in Microbiology
JF - Current Opinion in Microbiology
IS - 4
ER -